Teleflex Incorporated 2003 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Teleflex Incorporated (Teleflex)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 28, 2003
Business Overview: Teleflex operates in three diversified segments: Commercial (automotive, marine, industrial controls), Medical (disposable and reusable devices, surgical instruments), and Aerospace (cargo handling systems, turbine engine components). The company pursues growth through acquisitions and core product development, maintaining a conservative capital structure.
Key Financial Metrics
| Metric (in millions, except per share) | 2003 | 2002 |
|---|---|---|
| Revenues | $2,282.4 | $2,076.2 |
| Net Income | $109.1 | $125.3 |
| Diluted Earnings Per Share | $2.73 | $3.15 |
| Operating Cash Flow | $225.2 | $200.6 |
| Total Assets | $2,110.6 | $1,813.4 |
| Long-term Borrowings | $229.9 | $240.1 |
| Working Capital | $393.5 | $339.4 |
| Net Income Margin | 4.8% | 6.0% |
| Return on Average Equity | 11.1% | 14.8% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 10% to $2.28 billion, driven by gains in the Commercial and Medical segments which offset a decline in Aerospace. Acquisitions accounted for approximately 50% of the revenue increase, with the remainder due to favorable currency translation.
- Profitability Decline: Net income decreased 13% to $109.1 million. This was primarily due to a 73% drop in Aerospace operating profit (from $34.2M to $9.2M) caused by lower volume, contract losses, and new product development costs. Additionally, operating expenses as a percentage of revenue increased to 18.5% from 17.6%.
- Segment Performance:
- Commercial: Sales up 12% to $1.22 billion; operating profit up 2% to $101.6 million.
- Medical: Sales up 19% to $534.7 million; operating profit up 18% to $85.4 million, aided by the acquisition of Genzyme's cardiothoracic devices business.
- Aerospace: Sales down 2% to $528.6 million; operating profit collapsed to $9.2 million due to weak end markets in Industrial Gas Turbines and pricing pressures.
- Costs: Materials, labor, and product costs rose to 73.8% of revenues from 73.4% in 2002.
Guidance, Outlook, and Risks
- Strategic Objectives: Management targets 10-14% annual revenue growth, 14-18% net income growth, and a 17% return on average shareholders' equity. The company aims to maintain a debt-to-capitalization ratio between 30% and 40%.
- Outlook: Aerospace results are expected to improve in 2004 following substantial cost reductions implemented in 2003. Medical margins are expected to improve as acquisitions integrate.
- Liquidity: The company generated $225.2 million in operating cash flow. It maintains approximately $140 million in committed and $200 million in uncommitted lines of credit. Total debt to total capitalization decreased to 30%.
- Risks and Contingencies:
- Legal: A jury rendered a verdict against a subsidiary (Rusch, Inc.) in a trademark infringement case subsequent to year-end. The verdict included $2.6 million in reasonable royalties and $32.2 million in unjust enrichment. No judgment had been entered as of the filing date, and the company has not accrued the unjust enrichment amount.
- Environmental: Accrued liability for environmental remediation is $3.6 million, with potential liability ranging up to two or three times that amount over a 15-20 year period.
- Market: Exposure to foreign currency fluctuations (46% of borrowings are non-USD) and raw material cost increases.
Investor Verification Checklist
- Aerospace Turnaround: Verify the execution of cost reduction plans and the recovery of operating margins in the Aerospace segment for 2004.
- Legal Exposure: Monitor the final judgment amount and potential appeal outcomes regarding the Rusch, Inc. trademark verdict ($34.8 million total verdict).
- Acquisition Integration: Assess the financial contribution and margin impact of the 2003 acquisitions, particularly the Genzyme cardiothoracic business in the Medical segment.
- Environmental Liabilities: Review updates on environmental remediation costs, given the potential for liabilities to exceed current accruals.
- Debt Covenants: Confirm continued compliance with financial ratios required by senior and term note agreements, which limit dividends and stock repurchases.